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Abstract
Background: A peptide able to transduce cardiac tissue specifically, delivering cargoes to the heart, would be of significant
therapeutic potential for delivery of small molecules, proteins and nucleic acids. In order to identify peptide(s) able to
transduce heart tissue, biopanning was performed in cell culture and in vivo with a M13 phage peptide display library.
Methods and Results: A cardiomyoblast cell line, H9C2, was incubated with a M13 phage 12 amino acid peptide display
library. Internalized phage was recovered, amplified and then subjected to a total of three rounds of in vivo biopanning
where infectious phage was isolated from cardiac tissue following intravenous injection. After the third round, 60% of
sequenced plaques carried the peptide sequence APWHLSSQYSRT, termed cardiac targeting peptide (CTP). We demonstrate
that CTP was able to transduce cardiomyocytes functionally in culture in a concentration and cell-type dependent manner.
Mice injected with CTP showed significant transduction of heart tissue with minimal uptake by lung and kidney capillaries,
and no uptake in liver, skeletal muscle, spleen or brain. The level of heart transduction by CTP also was greater than with a
cationic transduction domain.
Conclusions: Biopanning using a peptide phage display library identified a peptide able to transduce heart tissue in vivo
efficiently and specifically. CTP could be used to deliver therapeutic peptides, proteins and nucleic acid specifically to the
heart.
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Introduction
Ischemic heart disease and occlusive coronary artery disease
continue to be the number one killer in the developed world.
There are an estimated 500,000 acute ST-elevation myocardial
infarctions (MI) in the US alone each year [1], and this is
becoming an increasingly significant problem in the developing
world [2]. Current approaches for management of an acutely
occluded coronary artery leading to an MI consist of anti-platelet
and anti-thrombotic strategies with intervention aimed at opening
the infarct-related artery in a timely fashion. Although this
approach is able to protect cardiomyocytes from necrosis, with
resulting decrease in morbidity and mortality, it necessitates
exposing the heart to post-ischemic reperfusion injury. Limiting
this reperfusion injury and decreasing apoptosis would ultimately
lead to greater myocardial salvage and prevention of development
of heart failure.
Numerous animal studies have identified biological agents able
to ameliorate this ischemia-reperfusion injury and reduce the
ultimate infarct size [3,4]. However, further development of these
approaches is hindered by the inability to deliver the biologic
agents to the myocardium in a tissue-specific, efficient and rapid
manner. A protein transduction peptide specific for the heart
would be able to deliver biologic agents in a timely fashion to the
heart when given at the time of reperfusion for an infarction.
Protein transduction domains (PTD) are small cationic peptides
that can cross cellular membranes, and are able to transport large,
biologically active molecules into mammalian cells in culture as well
as in vivo. The limitation of PTDs is the non-specific transduction of
all tissue types with some tissues, such as liver and kidney, taking up
thePTDmuch moreavidlythanhearttissue.Thusthereisaneedto
identify peptides able to target cardiac tissue specifically for delivery
of biologics of therapeutic potential.
Screening approaches using peptide phage display libraries are
effective for identifying peptidesableto bind to specific ligand targets
as well as identifying peptides with novel properties. Phage display
uses filamentous bacteriophage, such as M13, that are able to
replicateinE.coli.The proteins or peptidesto be displayed are fused
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present on the surface of the phage. Screening of peptide phage
display libraries has been used in vivo to identify peptides able to
target tumor vasculature [5], adipose tissue [6] and pancreatic islet
cells [7]. In addition, it has been used to identify peptides able to
facilitate internalization of intact, infectious phage into specific cell
types such as synovial fibroblasts [8]. In vivo phage display also has
been utilized to target atherosclerotic plaques [9], and to probe the
heart vasculature for endothelial markers [10]. Although in vitro
selection of a specific peptide sequence carrying phage resulted in
increased targeting of cardiomyocytes by phage in vivo [11], it
remains to be determined if the peptide can actually deliver ‘‘cargo’’
peptidesorproteinsoftherapeuticpotentialtotheheart.Ifsuch were
indeed the case, itwould open upnew avenues ofdrug development,
leading to delivery of therapeutics directly to the ischemic heart.
In the current study, we utilized a combinatorial approach of
cell culture and in vivo biopanning using an M13 phage peptide
display library to identify peptide(s) with potential for cardiomy-
ocyte transduction in vivo in a tissue specific manner. We have
identified a peptide, termed Cardiac Targeting Peptide or CTP
that is able to transduce cardiomyocytes specifically in culture and
in vivo. This peptide could be used to deliver peptides, proteins or
nucleic acid of therapeutic potential specifically to the heart.
Methods
Phage display
A combined approach of in vitro and in vivo screening of a phage
peptide display library for cardiomyocyte-specific transduction
peptides was utilized. Cardiomyoblasts, H9C2 cells (ATCC, CRL-
1446), were incubated with 10 ul (1610
11 pfu) of a 12-mer M13
phage peptide display library (NEB, E8110S), for 6 hours at 37uC,
5% CO2. Cells were then washed extensively, trypsinized and
lysed by a single freeze-thaw cycle. Recovered phage was tittered
and amplified. The post-amplified phage was again tittered and
administered intravenously by retro-orbital injection at a dose of
3.5610
11, to a female Balb/c mouse. The mice were pre-treated
with intra-peritoneal injection of Chloroquine (20 mg/Kg)
24 hours prior to and on the day of the phage injection, in order
to minimize intra-lysosomal destruction of internalized phage and
increase the chances of recovering internalized phage. The phage
was allowed to circulate for 24 hours, after which the mice were
euthanized and heart and kidney tissues obtained. The rationale
for this approach was based on the observation that after
intravenous injection, native M13 phage had a half-life in blood
of 4.5 hours [12]. Therefore we allowed the phage to circulate for
,5–6 half-lives to maximize the chance of uptake by cardiomy-
ocytes and minimize contamination with non-specific phage
circulating in the blood stream. To minimize the destruction of
internalized phage in lysosomal compartments, the mice were pre-
treated with Chloroquine, a drug known to increase the pH of
lysosomal compartments and theoretically decrease intracellular
destruction of phage. The collected tissues were digested with
collagenase and phage recovered by a single freeze/thaw cycle.
Recovered phage was then tittered, normalized by tissue weight
and subsequently amplified for a second round of biopanning. A
total of three in vivo biopanning rounds were performed followed
by sequencing of 10 plaques. All animal studies were approved by
the University of Pittsburgh Institutional Animal Care and Use
Committee (protocol approval number 0804422A-1).
Confocal microscopy
The cardiac targeting peptide (CTP) was synthesized in the
University of Pittsburgh Peptide Synthesis Facility in either 6-
carboxyfluorescene (CTP-6CF) labeled or biotinylated forms or
conjugated to NBD (Nemo-binding domain), an 11-amino acid
peptide (TALDWSWLQTE) which inhibits activation of the
inducible NF-kB Kinase (IKK) by binding to the regulatory
subunit (Nemo) of IKK.
A cardiomyoblast cell line (H9C2; ATCC, CRL-1446), a mouse
fibroblast cell line (NIH/3T3; ATCC, CRL-1658), a murine
fibrosarcoma cell line (C57/BL6 derived fibrosarcoma MCA-205
cell line, kindly provided by P. H. Basse, Dept. of Immunology,
University of Pittsburgh, Pittsburgh, PA), a cervical cancer cell line
(HeLa; ATCC, CCL-2), and a human kidney tubular cell line (HK-
2; ATCC, CRL-2190) were incubated with increasing concentra-
tions of CTP-6CF for 30 minutes. Cells were then washed 6 times
with PBS, fixed with 2% Paraformaldehyde, and counter-stained
withDRAQ5 (Molecular Probes, F1303), a nuclear stain.Cellswere
examined by confocal fluorescent microscopy.
Luciferase assays
H9C2 cells and MCA205 cells were transfected using
Lipofectamine (Invitrogen, 11668-027) with a reporter plasmid
expressing luciferase under an NF-kB promoter site as well as a
Renilla control plasmid for normalization of transfection efficien-
cies. Twenty-four hours later, cells were treated with increasing
concentrations of CTP-NBD and 30-minutes later challenged with
murine TNF-a, 10 ng/ml, for 3 hours. Cells were then washed,
trypsinized, lysed and supernatant collected for Luciferase activity
assay. Differences across groups were compared using an unpaired
Student’s t-test. A two-tailed p-value of ,0.05 was considered
statistically significant.
In vivo imaging studies
The initial in vivo targeting studies were performed using CTP-
6CF. Female Balb/C mice were injected retro-orbitally with CTP-
6CF (25 mg/Kg) and euthanized 15 minutes later. Heart cross-
sections were stained for actin using phalloidin Alexa- 647
(Molecular Probes, A22287) and stained for laminin using a
rabbit anti-laminin antibody followed by a goat anti-rabbit Cy3
(Jackson ImmunoResearch, 111-167-003) secondary antibody.
Five non-overlapping sections were taken from each heart for
quantification of green fluorescence (CTP-6CF) expressed as a
percentage of total area (blue; stained for actin).
A control peptide (CON; ARPLEHGSDKAT), picked from the
original, unselected M13 phage library, CTP and 8-Lysine (8K, a
homopolymer of lysine), a known cationic protein transduction
domain, were synthesized in a biotinylated form. 200 mMo f
biotinylated CTP, CON and 8K, or equivalent volume of PBS,
were incubated with 10 ul of Streptavidin-Alexa488 (2 ng/ml;
Molecular Probes, S32354) for 2 hours at room temperature.
Female Balb/c mice were intravenously (retro-orbitally) injected
with peptides at a dose of 10 mg/Kg and then euthanized 30
minutes post-injection. Mice were also injected with biotinylated
CTP conjugated to Streptavidin-Alexa488 at a dose of 10 mg/Kg
and euthanized after varying circulation times to allow for tracking
studies to be performed. Post-euthanasia heart, liver, lung, spleen,
kidney, skeletal muscle and brain were harvested for cryosection-
ing followed by confocal microscopy. Sections were cross-stained
with DRAQ5, a nuclear stain. For confocal microscopy, laser
intensities/gains were set using negative control (PBS injected)
heart tissue to minimize background fluorescence. Once the laser
intensity for FITC was set using the control hearts from PBS-
injected mice, it was kept constant across all subsequent imaging.
Also serial scanning was performed to prevent ‘‘bleed-through’’
from one laser wavelength to another.
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neutravidin-conjugated fluospheres (Molecular Probes, F8770)
with an overnight incubation at 4uC. These fluospheres are
40 nm in diameter and fluoresce at an excitation wavelength of
605 nm, allowing for in vivo bead tracking. Female Balb/c mice
received intracardiac injections of fluospheres-labeled CON
peptide, CTP peptide or control PBS incubated fluospheres alone.
Mice were anesthetized with isoflurane delivered by the XGI-8
Gas Anesthesia System (Xenogen). Initial isoflurane concentration
was set to 2.5% and was reduced to 1.5% once the animals were
anesthetized. Mice were then imaged at 30, 60, 120, and 180
minutes post-injection with the IVIS Lumina (Caliper Life
Sciences Inc.). All mouse studies were approved by the
Institutional Animal Care and Use Committee at the University
of Pittsburgh (protocol approval number 0804422A-1).
Results
Identification of a cardiac specific transduction peptide
by biopanning of a M13 phage display peptide library
In order to identify a peptide able to preferentially transduce cardiac
tissue in vivo,as c r e e n i n gp r o t o c o lu s i n ga1 2a m i n oa c i dp e p t i d eM 1 3
peptide phage display library was utilized. The first cycle of screening of
the phage peptide display library for cardiomyocytes specific
transduction peptides was performed on a rat cardiomyocyte cell line,
H9C2, in culture. The H9C2 cells were incubated with the M13 phage
peptide display library then washed extensively and possibly
internalized phage recovered following trypsinization and lysis by
freeze-thaw. For each of the subsequent three rounds, the phage were
injected intravenously and mice euthanized 24 hours post-injection.
The hearts and kidneys were isolated, enyzmatically digested and
associated phage recovered. The isolated phage were quantified and
expressed as number of phage per gram of tissue weight. Following
each round of in vivo screening, there was a steady increase in the ratio
of phage recovered from the heart relative to the kidneys, suggesting
enrichment of phage targeting the heart (Fig. 1). After the third round
of in vivo screening, 10 plaques were selected and sequenced. Six
of the 10 phage contained the identical nucleic acid sequence of
gcgccgtggcatctttcgtcgcagtattctcgtact, corresponding to the peptide APWHLSS-
QYSRT, termed cardiac targeting peptide (CTP). A BLAST search in
the NCBI database revealed that this sequence shared no homology
with known naturally occurring peptides or proteins.
Confocal microscopy analysis demonstrates preferential
targeting of cardiomyoblasts
In order to examine the ability of CTP to transduce cardiomyocytes
preferentially in a dose-dependent manner, fluorescent confocal
microscopy was performed using the peptide coupled to 6-carboxy-
flouroscene (6-CF). H9C2, 3T3, MCA-205, HeLa and HK-2 cells were
incubated with increasing concentrations of CTP-6-CF, washed, fixed
and counterstained with DRAQ5, a nuclear stain. As shown in figure 2,
significant internalization of CTP-6-CF was observed in H9C2 cells
compared to relatively minor internalization by 3T3, MCA-205 and
HeLa cells at high concentrations, with no appreciable uptake by
HK-2 cells. These results, performed by confocal analysis, demonstrate
both the specificity of transduction by CTP as well as that the peptide
is internalized, and not simply binding to the cell membrane.
Inhibition of IKK/NF-kB signal transduction by a CTP-NBD
fusion peptide demonstrates functional delivery to
cardiomyoblasts
To confirm functional transduction of H9C2 cells by CTP, the
ability to deliver a peptide, NBD, able to block activation of the
IKK/NF-kB transduction pathway, was examined. H9C2 and
MCA205 cells were transfected with a plasmid expressing the
luciferase marker under the control of a NF-kB-dependent
promoter. Twenty-four hours post-transfection, cells were pre-
treated with the CTP-NBD fusion peptide for 30 minutes, followed
by stimulation with murine TNF-a for three hours. TNF-a
treatment alone caused an increase in NF-kB transcriptional
activity, which was inhibited by pre-treating the H9C2 cells with
increasing concentrations of CTP-NBD, in a dose-dependent
fashion (Fig. 3-a). In contrast, experiments performed using
MCA205 cells did not show any inhibition of TNFa mediated
NF-kB activation (Fig. 3b).
CTP transduces cardiac tissue in vivo
To demonstrate transduction of heart tissue in vivo, CTP-6CF or
the biotinylated forms of CTP, RAN and 8K peptides coupled to
Streptavidin-Alexa 488 (SA488) were injected intravenously (retro-
orbitally). Mice were euthanized at varying time points and heart
and multiple other organs harvested for confocal microscopy.
Confocal microscopy of heart tissue from mice injected with CTP-
6CF showed rapid (15 minutes) transduction of heart tissue (Fig. 4).
Staining for actin and laminin showed co-localization of CTP-6CF
fluorescence (green; Figure 4a) with actin (blue; Figure 4b), but not
laminin (red; Figure 4c). These co-localization studies strongly
suggest that CTP is internalized into cardiac cells in vivo, similar to
the cell culture experiments. Quantification of transduction, using
Metamorph software, revealed that approximately 15% of the
total heart was being transduced by CTP following intravenous
injection (Fig. 4e).
Injection of the CTP-biotin-SA488 complex showed rapid,
efficient and specific transduction of heart tissue at 30 minutes in a
diffuse pattern compared to Streptavidin-Alexa 488 alone. There
was no appreciable transduction seen of liver, skeletal muscle,
Figure 1. Enrichment of cardiac specific phage by multiple
rounds of biopanning. After a single, screening cycle of phage
incubated with H9C2 cells, recovered phage was amplified, tittered and
injected intravenously into Balb/c mice. After a circulation time of
24 hours, mice were euthanized, heart and kidney dissected, digested
with collagenase II, cells lysed and recovered phage tittered. Recovered
phage was amplified, re-tittered and injected for subsequent round of
biopanning. Phage recovered from heart versus kidney from each cycle
of in vivo phage display was normalized by gram of tissue weight and
expressed as a ratio of heart to kidney.
doi:10.1371/journal.pone.0012252.g001
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with uptake were a small percentage of lung capillaries as well as
limited transduction of endothelial cells of the glomerular
capillaries in the cortex of the kidneys (Fig. 5). These results
demonstrate the specificity of CTP transduction in vivo.
To examine the biodistribution of CTP-biotin-SA488 over time,
mice were euthanized at different time points following intrave-
nous injection. Even with the large CTP-biotin-SA488 complex,
efficient transduction of the heart was seen at 15 minutes, mainly
confined to the sub-epicardial region of the heart. At 30 minutes
this became more diffuse and by 120 minutes there was almost no
fluorescence seen in the heart (Fig. 6). Over these three time
points, the fluorescence gradually increased in the kidney
glomerular capillaries (Fig. 6, center column), suggesting that this
might be the mode of excretion of this peptide or at least the
fluorescence after peptide breakdown.
Figure 2. CTP specifically transduces cardiomyocytes in culture. Confocal micrographs of H9C2, 3T3, MCA-205, HeLa and HK-2 cells
incubated with increasing concentrations (50 uM, 100 uM and 200 uM) of CTP-6CF for 30 minutes, followed by multiple washings and cross-staining
with a nuclear stain, DRAQ5 (206) (a). A higher (406) confocal micrograph of H9C2 cells is shown demonstrating pattern of transduction (b); CTP-6CF
- green, Nuclei – blue. Scale bars represent 100 uM.
doi:10.1371/journal.pone.0012252.g002
Figure 3. CTP functionally delivers the IKK/NF-kB inhibitory peptide NBD to cardiomyocytes. H9C2 cells (a) and MCA205 (b) cells, were
co-transfected with a NF-kB dependent luciferase reporter plasmid and a control renilla-expression plasmid. Twenty-four hours post-transfection,
cells were stimulated with TNF-a (10 ng/ml) or pre-treated with increasing concentrations of CTP-NBD (50 uM, 100 uM, 200 uM and 400 uM) for 30
minutes followed by TNF-a stimulation for three hours. Cells were then washed, lysed and luciferase activity measured and normalized to renilla
activity. (N=4 in each group; error bars represent one standard deviation).
doi:10.1371/journal.pone.0012252.g003
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tissue in vivo, the peptide was coupled to fluospheres that allow for
analysis of localization by whole animal imaging. Balb/c mice
were injected intracardiac with 40 nm neutravidin-labeled fluo-
spheres alone, CTP-biotin and CON-biotin labeled with these
fluospheres. Mouse imaging was performed at baseline and 30, 60,
120 and 180 minutes. CTP+fluospheres were retained in the heart,
as opposed to fluospheres alone or CON+fluospheres, which
dissipated immediately after injection. CTP+fluospheres could still
be found localized to the heart at 3 hours post-injection (Fig. 7).
To determine the relative efficiency as well as specificity of
transduction of cardiac tissue by CTP, the transduction ability of
Figure 4. Internalization and quantification of transduction by CTP-6CF in cardiac tissue in vivo. Cross-sections of mouse heart were
stained for actin (blue) and laminin (red). Confocal microscopy showed co-localization of CTP-6CF (a) with actin (b) but not laminin (c) as seen in the
color-merged micrograph (d). FITC fluorescence from non-overlapping heart micrographs from mice injected with CTP-6CF (n=3) or PBS (n=3) was
quantified and expressed as a percentage of total area calculated from staining for actin (Fig. 4e; error bars represent standard error of the mean).
CTP-6CF – green; Actin – blue; Laminin – red. Scale bars represent 100 uM.
doi:10.1371/journal.pone.0012252.g004
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transduction domain. Mice were injected with 10 mg/Kg dose of
either CTP-SA488, 8K-SA488 or CON-SA488 conjugate and
euthanized 30 minutes post-injection (Fig. 8). Mice treated with
8K-SA488 showed robust transduction of hepatocytes as well as
kidney glomeruli with very little uptake in heart tissue. In contrast,
CTP-SA488 conjugate showed only robust transduction of heart
tissue with some uptake in the kidney glomerular capillaries and
none by liver or spleen. The CON-SA488 complex did not show
appreciable uptake in any organ.
It is important to note that all of the analysis of CTP
transduction in vivo was performed with the L-form, the naturally
occurring form, of the peptide. Preliminary experiments using a
non-degradable D-form have shown a far more efficient
transduction that persists for extended periods of time (data not
shown). Thus, it appears that there is degradation of the L-CTP
complexes over time.
Discussion
The clinical application of potentially effective biological
therapies for common acute cardiac conditions, like myocardial
infarction, has been limited by efficiency and specificity of delivery
of therapeutic agents. For example, for gene therapy approaches,
such as plasmid DNA, delivery to the heart is very inefficient
whereas there are significant time delays associated with cardiac
Figure 6. Pattern of distribution of CTP-biotin-SA488 over time in vivo. Mice were injected intravenously with CTP-biotin-SA488 (10 mg/Kg)
and euthanized 15, 30 or 120 minutes post-injection. Heart, kidneys and liver were cross-sectioned, counter-stained with DRAQ5 and confocal
microscopy performed. N=1 in each group; scale bars represent 100 uM.
doi:10.1371/journal.pone.0012252.g006
Figure 5. CTP specifically transduces cardiac tissue in vivo. Confocal analysis (206) was performed on tissues from heart, liver, kidney, lung,
skeletal muscle and brain (a–f) from mice euthanized 30 minutes after intravenous injection of CTP-biotin-SA488 conjugate (10 mg/Kg) or
PBS+SA488. Slides were counter-stained with DRAQ5, a nuclear stain. CTP-SA488 – green, Nuclei – blue. N=3 in each group; scale bars represent
100 uM.
doi:10.1371/journal.pone.0012252.g005
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issues regarding the presence of pre-existing neutralizing antibod-
ies or immune responses to certain viral vectors. The well-
characterized cell penetrating peptides, like TAT from HIV coat
protein, homopolymers of arginine or lysine, are not cell specific
and transduce hepatocytes and multiple other organs in addition
to the heart. Therefore, identifying a peptide with transduction
capabilities specific for the heart would allow for new approaches
for effective cardiac delivery of therapeutics.
We previously have reported the ability to identify a synovial
specific transduction peptide by screening an M13 phage peptide
display library for internalized phage [8]. Thus we screened a
large phage peptide display library in order to identify novel
peptides potentially able to transduce cardiomyocytes in vivo.
Indeed, we report here the identification of a specific peptide,
termed CTP, which 15 or 30 minutes post-peripheral intravenous
injection can efficiently and specifically transduce cardiac tissue
(Fig. 4 and 5 respectively). Transduction of cardiomyocytes on
confocal microscopy of cross-sections of the mouse heart occurred
in a diffuse manner, though there appeared to be some preference
for the subendocardial and subepicardial regions at earlier time
point of 15 minutes. No other organ showed uptake except kidney
glomeruli, limited to the cortex, and rare lung capillaries, to a
much lesser extent than heart tissue. Furthermore, CTP was able
to transduce heart tissue in vivo far more efficiently and in a tissue-
specific manner as compared to 8-Lysine, a known PTD (Fig. 7).
Since the initial description of in vivo screening of phage display
libraries by Pasqualini and Ruoslahti [13], this approach has been
utilized to identify peptides that target tumor vasculature [5],
adipose tissue [6], pancreatic islet cells [7], synoviocytes [8],
Figure 7. CTP targets fluospheres to the heart. Whole mouse in vivo imaging was performed following intra-cardiac injection of fluospheres
alone, CTP+fluospheres and RAN+fluospheres at 30, 60, 120 and 180 minutes, at a dose of 10 mg/Kg of body weight (for peptides). (N=3 in each
group).
doi:10.1371/journal.pone.0012252.g007
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This approach also has been used in cell culture with adherent
primary cardiomyocytes to isolate a 20-mer peptide with a
homology to tenascin-X [11], an extracellular matrix protein. The
phage displaying this peptide was found to be associated with
cardiomyocytes isolated from mice treated with it in vivo. However,
although it was preferentially associated with cardiomyocytes, it
could still be isolated from lung tissue. Furthermore, it was unclear
whether this 20-mer peptide was able to function as a cardiac
transduction domain and transduce heart tissue in vivo independent
of the phage carrying it.
In our screening approach, we combined a combination of cell
culture and in vivo screening to identify a peptide able to be
internalized into cardiac tissue. The first cycle was performed on
cardiomyocytes as a screening approach to limit the population of
non-specific phage from the initial phage library. All subsequent
cycles were in vivo with intravenous injection in mice followed by a
prolonged circulation time of 24 hours. Using this approach we
identified a peptide that is able to deliver fluorescently labeled
Streptavidin, a ,60 kDa complex, to cardiac cells in vivo without
transduction of liver, spleen, skeletal muscle or brain, with minimal
uptake by lung and glomerular capillaries. A BLAST search in the
NCBI data base did not reveal homology to any known, naturally
occurring proteins.
Interestingly two separate groups of investigators, using an in
vitro screening of a phage display library approach, have identified
the exact same sequence as CTP, and shown it to have high
affinity for binding to apatite-based, bone-like minerals [14] and
two specific sulfated carbohydrates [15]. However, it is unclear
how the ability of CTP to interact with these cellular components
Figure 8. CTP specifically transduces cardiac tissue in contrast to a cationic transduction domain. Confocal analysis of heart, kidney, liver
and spleen (a–d) 30 minutes following intravenous injection of CTP+SA488, 8K+SA488 or RAN+SA488 (10 mg/Kg body weight) conjugates. N=2 in
each group; scale bars represent 100 uM.
doi:10.1371/journal.pone.0012252.g008
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currently are examining whether the transduction process is
energy independent as well as whether it involves endocytosis.
Also, the size limitation for the cargo to be delivered is unknown,
but presumably it is as large as or larger than the M13 phage used
for the identification of the peptide.
Given the fact that CTP-mediated transduction of cardiac tissue
is efficient, specific and rapid, it could be used to deliver a variety
of proteins, peptides, small molecules and viral and non-viral gene
transfer vectors to the heart for treating cardiac conditions. In
addition, it could be used diagnostically to determine the extent of
viable cardiac tissue following infarct or ischemia reperfusion
injury. Overall, the identification of a heart-specific delivery
peptide should allow for novel biological treatments for cardiac
conditions.
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